MNKD
$4.15
Mannkind
($.01)
(.24%)
MNKD
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.05)
Revenue:  $19.51 Mil
Wednesday
Nov 10
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when MNKD reports earnings?
Beat
Meet
Miss

Where is MNKD's stock price going from here?
Up
Flat
Down
Stock chart of MNKD
Analysts
Summary of analysts' recommendations for MNKD
Score
Grade
Pivots
Resistance
$4.52
$4.41
$4.28

$4.18

Support
$4.05
$3.94
$3.81
Tweet
Growth
Description
Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung.
Peers
Vertex PharmaceuticalsUltragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbInterCeptMerck & Co.Eli LillyZoetisPfizer